Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Ref. No: ADL/SE-2M/2016
Date : 5th February, 2016

To,
Listing/Compliance Department
BSE LTD.

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.
BSE CODE –524348

To,
Listing/Compliance Department
National Stock Exchange of India Limited
"Exchange Plaza", Plot No. C/1,
G Block Bandra-Kurla Complex,
Bandra (E), Mumbai – 400 051.
NSE CODE:AARTIDRUGS

Dear Sir/Madam,

Please find enclosed herewith copy of press release issued by the company on 5th February, 2016.

Kindly take the note of the above.

Thanking You

Yours faithfully,
For **AARTI DRUGS LIMITED**

HARSHIT M. SAVLA
JT. MANAGING DIRECTOR
Encl: as above.

Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Press release for Dec' 2015:

Macroeconomic factors that are unfavourable to global trade, continues to impact the export sales and indirectly the domestic sales, which are related to formulation exports. In spite of this, company has shown good growth in the domestic markets.

Consolidated EBITDA for the period ended Dec' 15 is 129.93 crores, up by 3.07%, indicating stable operational efficiency. Profit before tax has gone down on account of higher depreciation and interest costs, due to commissioning of various expansion projects. Company has taken swift action to reduce inventory levels to be adaptable to face current industry challenges.

Expansion project of anti- diarrheal product went live in Dec'15 quarter which will give boost to sales in future. Company seeks to get regulatory approvals for its new anti-biotic facility, which will give impetus to topline in near future. Company is actively seeking for re-inspection from USFDA authorities, to restart its USA business.

For **AARTI DRUGS LIMITED**

HARSHIT M. SAVLA
JT. MANAGING DIRECTOR